The efficacy and adverse events of arsenic trioxide for the patients with myelodysplastic syndrome: a systematic review and component network meta-analysis

References

• Bokorová R, Fuchs O, Myslivcova D, et al. Arsenic trioxide upregulates cereblon mRNA expression and potentiates sensitivity of SKM-1 and MDS-L cells to lenalidomide. Blood. 2019;134(Supplement_1):5397. doi:10.1182/blood-2019-126443
   Google Scholar
• Vey N, Bosly A, Guerci A, et al. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol. 2006 Jun;24(16):2465–2471. doi:10.1200/JCO.2005.03.9503
   PubMedGoogle Scholar
• Schiller GJ, Slack J, Hainsworth JD, et al. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol. 2006 Jun;24(16):2456–2464. doi:10.1200/JCO.2005.03.7903
   PubMedGoogle Scholar
• Zandberg DP, Huang TY, Ke X, et al. Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults. Haematologica . 2013 Apr;98(4):584–590. doi:10.3324/haematol.2012.062547
   PubMed Web of Science ®Google Scholar
• Gangat N, Patnaik MM, Begna K, et al. Primary myelodysplastic syndromes: The Mayo Clinic experience With 1000 patients. Mayo Clin Proc. 2015 Dec;90(12):1623–1638. doi:10.1016/j.mayocp.2015.08.022
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savovic J, Page MJ, et al. Rob 2: a revised tool for assessing risk of bias in randomised trials. Br Med J. 2019 Aug;366:l4898. doi:10.1136/bmj.l4898
   PubMed Web of Science ®Google Scholar
• Rucker G, Petropoulou M, Schwarzer G. Network meta-analysis of multicomponent interventions. Biom J. 2020 May;62(3):808–821. doi:10.1002/bimj.201800167
   PubMed Web of Science ®Google Scholar
• Shim SR, Kim SJ, Lee J, et al. Network meta-analysis: application and practice using R software. Epidemiol Health. 2019;41:e2019013. doi:10.4178/epih.e2019013
   PubMed Web of Science ®Google Scholar
• Rucker G, Schmitz S, Schwarzer G. Component network meta-analysis compared to a matching method in a disconnected network: A case study. Biom J. 2021;63(2):447–461. doi:10.1002/bimj.201900339
   PubMed Web of Science ®Google Scholar
• Kropf PL, Shameem R, Pancari PA, et al. Improved survival for MDS/CMML patients treated with the combination of decitabine (DAC) and arsenic trioxide (ATO) in a phase II adaptive three arm randomization study: DAC alone Vs. DAC +/-Carboplatin or ATO. Blood [Conference Abstract]. 2016;128(22):3170. doi:10.1182/blood.V128.22.3170.3170
   Web of Science ®Google Scholar
• Wei W, Zhou F, Zhang Y, et al. A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes. Leukemia Res. 2012;36(6):715–719. doi:10.1016/j.leukres.2011.12.023
   PubMed Web of Science ®Google Scholar
• Bu YW. The clinical research of arsenic trioxide combined with thalidomide in the treatment of patients with intermediate-1 MDS. J Jining Med Univ. 2016;39(04):245–247.
   Google Scholar
• Zeng YJ, Liang ZY, Peng GR, et al. Turmeric enhanced the efficacy of arsenic trioxide combining with thalidomide for patients with myelodysplastic syndrome. Jiangxi J Trad Chinese Med. 2021;52(11):31–33.
   Google Scholar
• Zeng ZY. Efficacy and safety of Arsenious Acid and Thalidomide in the treatment of myelodysplastic syndrome. Contemp Med. 2018;24(11):76–78.
   Google Scholar
• Chen QW, Zhang L, Lu JH, et al. The clinical observation of arsenic trioxide combined with Jianpibushenjiedu Fomula for elderly patients with MDS-RAEB. Liaon J Trad Chinese Med. 2011;38(9):1841–1843.
   Google Scholar
• Dang HB. The analysis of thalidomide combinded with arsenic trioxide for 38 patients with myelodysplastic syndrome. Chongqing Med. 2014;43(14):1791–1793.
   Google Scholar
• Deng LL. Efficacy analysis of arsenic trioxide combining with thalidomide for patients with intermediate risk-1 myelodysplastic syndrome. Diet Health. 2018;5(39):78.
   Google Scholar
• Guo SL. Applicating arsenic trioxide for the treatment of myelodysplastic syndrome-refractory anemia with excess blasts. China Pract Med. 2012;7(24):195–196.
   Google Scholar
• Guo TJ, Gong JM, Wu BJ, et al. Clinical observation on arsenic trioxide combined with cytarabine in the treatment of 38 patients with myelodysplastic syndrome. China Med Herald. 2012;9(9):80–1,4.
   Google Scholar
• Huang PC, Si YH, Mo SY. Effect of arsenic trioxide combined with thalidomide in the treatment of myelodysplastic syndrome. Guide China Med. 2020;18(14):77–78.
   Google Scholar
• Li HY. Comparative analysis of arsenic trioxide and HAG for the treatment of myelodysplastic syndrome. J North Pharm. 2017;14(02):174–175.
   Google Scholar
• Li HM, Liu LN, Mei ZY, et al. Analysis of effect of ultra-low dose of decitabine and arsenic acid in treatment of myelodysplastic syndrome. J Med Forum. 2018;39(1):1–26.
   Google Scholar
• Li SM. Clinical trial of arsenic trioxide in the treatment of patients with middle and high risk myelodysplastic syndrome. Chin J Clin Pharmacol. 2017;33(23):2364–2367.
   Google Scholar
• Li YQ, Liang ZW, Luo GZ. Compound Zaofan pill combined with low dose cytarabine, arsenic trioxide treatment syndrome randomized controlled trial of abnormal comprehensive geriatric bone marrow hyperplasia. J Pract Tradition Chin Intern. 2013;27(06):102–104.
   Google Scholar
• Liang YN LISL. Efficacy analysis of arsenic trioxide plus thalidomide for myelodysplastic syndrome. J Med Theor Pract. 2013;26(17):2312–2313.
   Google Scholar
• Liang YN, Qin YL. Analysis of the clinical effect of arsenious acid combine with thalidomide for treating myelodysplastic syndrome. J Yanan Univers(Med Sci). 2015;13(2):32–34.
   Google Scholar
• Liu H. The clinical value of As2O3+ Ara-c in treating the patients with MDS. J Hunan Norm Univer(Med Sci). 2016;13(6):20–23.
   Google Scholar
• Liu WX, He T, Wang T, et al. The clinical efficacy observation of patients with myelodysplastic syndrome treated by arsenic trioxide combining with thalidomide. China Health Care Nutrition. 2013;10:589–590.
   Google Scholar
• Luo ZY. Combination treatment of arsenic trioxide and thalidomide for patients with myelodysplastic syndrome: efficacy and adverse events. Contempor Med. 2017;23(03):33–34.
   Google Scholar
• Su JM, Zhang C, Rong TJ, et al. Combination treatment of arsenic trioxide and thalidomide for patients with myelodysplastic syndrome. Shanxi Med J. 2017;46(05):559–562.
   Google Scholar
• Sun F, Gao MJ, Yong YL. The 30 instances clinical observation of “Bushen Jiedu Recipe” and arsenious acid in treating myelodysplastic syndrome. Liaon J Tradition Chin Med. 2014;41(8):1656–1658.
   Google Scholar
• Tian Y. Clinical study on myelodysplastic syndrome. China Clin Practl Med. 2010;04(5):32–33.
   Google Scholar
• Wang FY. Combination of thalidomide, calcitriol and andarsenic trioxide in the treatment of myelodysplastic syndrome. Hainan Med J. 2009;20(11):42–44.
   Google Scholar
• Wang GJ, Tian Y. Effect of arsenious acid combined with thalidomide on patients with myelodysplastic syndromes. J Med Forum. 2018;39(7):55–57.
   Google Scholar
• Wang GY, Ma HH, Zhao JS. Clinical value study about the combining application of arsenic trioxide and thalidomide for 85 cases with myelodysplastic syndrome. Cardiovas Diseas J Integrat Trad Chin Wester Med(Electron). 2019;7(26):187–188.
   Google Scholar
• Wang JX, Zhang QR. The regulative effect of arsenic trioxide plus thalidomide for myelodysplastic syndrome. Modern J Integrat Tradition Chin Western Med . 2013;22(24):2679–2681.
   Google Scholar
• Wu CN, Song GC, Zhang J. Efficacy of arsenic trioxide in the treatment of elderly patients with high risk of bone marrow hyperplasia syndrome. Sichuan Med J. 2017;38(01):66–68.
   Google Scholar
• Yang HP, Zhao XQ, Hu M. Arsenic trioxide associated with large-dose ascorbic acid, thalidomide in treatment of 20 patients with myelodysplastic syndrome. J Hen Univ Sci Techn (Med Sci). 2011;29(04):280–282.
   Google Scholar
• Yu SM. An explorative research of patients with myelodysplastic syndrome treated by thalidomide, arsenic trioxide and Rocaltrol. Guide China Med. 2017;15(08):68–69.
   Google Scholar
• Zhang J, Xu JG. Comparison of between arsenic trioxide and HAG regimen in the treatment of myelodysplastic syndrome. Sichuan Med J. 2012;33(10):1793–1795.
   Google Scholar
• Zhang QR, Chen LS, Wang JX, et al. Effects of arsenic trioxide plus thalidomide on immune function in patients with myelodysplastic syndrome. Clinic Med China. 2013;29(12):1243–1246.
   Google Scholar
• Zhang QR, Chen LS, Zhang GH, et al. The efficacy observation of the regimen majoritve with arsenic trioxide for elderly high risk patients with myelodysplastic syndrome. Chin J Clinic (Electron Edit). 2011;5(16):4895–4896.
   Google Scholar
• Zhao XQ, Wu YL, Yang HP. Clinical analysis of thalidomide, arsenic trioxide and calcitriol treating myelodysplastic syndrome]. Chinese J. Trauma Disabil Med. 2016;24(18):17–18.
   Google Scholar
• Zhao XQ, Yang HP. Exploration and analysis of the therapeutic value of arsenic trioxide combined with thalidomide for patients with myelodysplastic syndrome. J ShanDong First Med Univers ShanDong Academ Med Sci. 2017;38(04):414–415.
   Google Scholar
• Zhong JW, Luo C, Zhao CF, et al. Effect observation of thalidomide combined with arsenious acid in the treatment of myelodysplastic syndrome. Chinese J Pharmacoepidemiol. 2017;26(4):234–236.
   Google Scholar
• Zhu CX. Investigate the effect of arsenic trioxide combined with thalidomide in the treatment of myelodysplastic syndrome. China Foreig Med Treatm. 2020;39(13):99–101.
   Google Scholar
• Zuo AL. A combination of arsenic trioxide and CAG for patients with myelodysplastic syndrome. Tianjin Med J. 2010;38(11):1007–1008.
   Google Scholar
• Zhang YZ, Xie SY, Sun Y. Effects of decitabine combined with arsenic trioxide regimen on immune function in patients with myelodysplastic syndrome undergoing chemotherapy. Contemp Med. 2022;28(13):148–150.
   Google Scholar
• Greenberg PL, Stone RM, Al-Kali A, et al. Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(1):60–87. doi:10.6004/jnccn.2017.0007
   PubMed Web of Science ®Google Scholar
• Zhang ZN. Diagnosis and efficacy criteria of hematological disease (version 2). Yang CL, editor. Beijing: China Science Publishing and Media Ltd; 1998.
   Google Scholar
• Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000 Dec;96(12):3671–3674.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD. Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia. Blood 2006 Jul 108(2):419–425. doi:10.1182/blood-2005-10-4149
   PubMed Web of Science ®Google Scholar
• Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007 Mar;109(6):1114–1124. doi:10.1002/cncr.22496
   PubMed Web of Science ®Google Scholar
• Wei G, Ni W, Chiao JW, et al. A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol. 2011;14(4):46. doi:10.1186/1756-8722-4-46
   Google Scholar
• Xie M, Jiang Q, Li L, et al. HAG (Homoharringtonine, Cytarabine, G-CSF) regimen for the treatment of acute Myeloid Leukemia and Myelodysplastic syndrome: A meta-analysis with 2,314 participants. PLoS One. 2016;11(10):e0164238.
   PubMed Web of Science ®Google Scholar
• Hua HY, Gao HQ, Sun AN, et al. Arsenic trioxide and triptolide synergistically induce apoptosis in the SKM–1 human myelodysplastic syndrome cell line. Mol Med Rep. 2016;14(5):4180–4186. doi:10.3892/mmr.2016.5779
   PubMed Web of Science ®Google Scholar
• Huang L, Liu Z, Jiang H, et al. Decitabine shows synergistic effects with arsenic trioxide against myelodysplastic syndrome cells via endoplasmic reticulum stress-related apoptosis. J Investig Med. 2019 Oct;67(7):1067–1075. doi:10.1136/jim-2018-000953
   PubMed Web of Science ®Google Scholar
• Wu X, Hu Z, Nizzero S, et al. Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity. J Control Release. 2017 Dec;268:92–101. doi:10.1016/j.jconrel.2017.10.012
   PubMed Web of Science ®Google Scholar
• Galimberti S, Guerrini F, Salvi F, et al. Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study. J Hematol Oncol. 2012 Sep;5:53. doi:10.1186/1756-8722-5-53
   PubMed Web of Science ®Google Scholar
• Shao X, Lu R, Guan X, et al. [Effects of arsenic trioxide on Id4 methylation status in bone marrow mononuclear cells and its clinical efficacy for myelodysplastic syndrome]. Zhonghua Xue Ye Xue Za Zhi. 2014 Mar;35(3):247–250.
   PubMedGoogle Scholar
• Zhou QB, Zhu QZ, Wang HZ, et al. Traditional Chinese medicine containing arsenic treated MDS patients effectively through Regulating Aberrant Hypomethylation. Evid Base Complem Altern Med. 2020;2020:7469809.
   PubMed Web of Science ®Google Scholar
• Hollow SE, Johnstone TC. Realgar and arsenene nanomaterials as arsenic-based anticancer agents. Curr Opin Chem Biol. 2023 Feb;72:102229. doi:10.1016/j.cbpa.2022.102229
   PubMed Web of Science ®Google Scholar